First year LAMP results: 0.05% atropine reduces myopic progression

In the first phase of the ongoing four-phase LAMP study, researchers report 0.05% atropine was most effective among three concentrations and placebo in controlling spherical equivalent and axial length in children with myopia.
The treatment phase of the Low-concentration Atropine for Myopia Progression (LAMP) double-masked study randomized 438 children aged 4 to 12 years to receive 1:1:1:1 either low dose atropine eye drops at concentrations of 0.05%, 0.025% or 0.01% or placebo eye drops in both eyes daily for 12 months.
A total of 383 participants were evaluated at the (Read more...)

Full Story →